Atypical Withdrawal Symptoms after Abrupt Tramadol Discontinuation: A Case Report.

IF 0.9 Q3 ANESTHESIOLOGY Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-11-28 DOI:10.1080/15360288.2023.2261913
Caylee Sams, Serena Cheng
{"title":"Atypical Withdrawal Symptoms after Abrupt Tramadol Discontinuation: A Case Report.","authors":"Caylee Sams, Serena Cheng","doi":"10.1080/15360288.2023.2261913","DOIUrl":null,"url":null,"abstract":"<p><p>Tramadol is a commonly utilized analgesic in the United States. One common misconception is that tramadol is safer than other opioid medications, or less likely to cause physical dependence. Given these misconceptions, the likelihood of patients experiencing withdrawal after discontinuation may be commonly overlooked as well. A 68-year old female patient with fibromyalgia was referred to a clinical pharmacy pain clinic for medication management. The patient was evaluated one month after abrupt discontinuation of tramadol 50 mg every 6 h for at least 10 years of use. She reports concerning symptoms of significant mucus production, fullness in chest and soreness in neck. Although tramadol is a Schedule IV Controlled Substance the risk of physical dependence and likelihood of patients experiencing withdrawal symptoms after abrupt cessation should not be diminished. Tramadol should not be considered a \"safer\" opioid therapy without potential of classic or atypical withdrawal symptoms, as well as risk of abuse, misuse or addiction.</p>","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain & Palliative Care Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15360288.2023.2261913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tramadol is a commonly utilized analgesic in the United States. One common misconception is that tramadol is safer than other opioid medications, or less likely to cause physical dependence. Given these misconceptions, the likelihood of patients experiencing withdrawal after discontinuation may be commonly overlooked as well. A 68-year old female patient with fibromyalgia was referred to a clinical pharmacy pain clinic for medication management. The patient was evaluated one month after abrupt discontinuation of tramadol 50 mg every 6 h for at least 10 years of use. She reports concerning symptoms of significant mucus production, fullness in chest and soreness in neck. Although tramadol is a Schedule IV Controlled Substance the risk of physical dependence and likelihood of patients experiencing withdrawal symptoms after abrupt cessation should not be diminished. Tramadol should not be considered a "safer" opioid therapy without potential of classic or atypical withdrawal symptoms, as well as risk of abuse, misuse or addiction.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
曲马多突然停药后的非典型戒断症状:一例报告。
曲马多是美国常用的止痛药。一个常见的误解是,曲马多比其他阿片类药物更安全,或者不太可能引起身体依赖。鉴于这些误解,患者在停药后出现戒断症状的可能性通常也会被忽视。一名患有纤维肌痛的68岁女性患者被转诊到临床药房疼痛诊所进行药物管理。患者在曲马多50突然停药一个月后接受评估 mg每6 h至少10 使用年限。她报告了大量粘液分泌、胸部胀满和颈部酸痛的症状。尽管曲马多是附表四管制物质,但不应降低患者突然停止服用后出现身体依赖性和戒断症状的可能性。曲马多不应被视为一种“更安全”的阿片类药物治疗,而不会出现典型或非典型的戒断症状,以及滥用、误用或成瘾的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.60
自引率
9.10%
发文量
40
期刊最新文献
Editorial: Reasons for Conflicting Evidence Regarding Use of Platelet-Rich Plasma (PRP). The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials. Changes in Pain and Mental Health Symptoms Associated with Prescribed Medicinal Cannabis Use: A One-Year Longitudinal Study. Correction. Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1